Louise Rodino-Klapac, Sarepta's president of R&D. Shares in Sarepta Therapeutics lost nearly 40% of their value after the company said a trial designed to confirm the efficacy of two already-marketed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results